 | Emily Edson‐Heredia |
Prominent publications by Emily Edson‐Heredia
BACKGROUND: Plaque psoriasis affects children and adults, but treatment options for paediatric psoriasis are limited.
OBJECTIVES: To evaluate the efficacy and safety of ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, for moderate-to-severe paediatric psoriasis.
METHODS: In a randomized, double-blind, placebo-controlled, phase III study (IXORA-PEDS), patients aged 6 to < 18 years with moderate-to-severe plaque psoriasis were randomized 2 : 1 ...
| Also Ranks for: Paediatric Patients | ixekizumab ixe | severe plaque | efficacy safety | treatment moderate |
IMPORTANCE: Therapies that reduce psoriasis symptoms may improve work productivity.
OBJECTIVE: To assess the effect of ixekizumab therapy on work productivity, measured by the Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO).
DESIGN, SETTING, AND PARTICIPANTS: Three multicenter, randomized double-blind phase 3 trials conducted during the following periods: December 2011 through August 2014 (UNCOVER-1), May 2012 through April 2015 (UNCOVER-2), and August 2012 through July ...
| Also Ranks for: Work Productivity | ixekizumab treatment | week patients | activity impairment | phase 3 |
BACKGROUND: Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment.
METHODS: In our phase 2, double-blind, placebo-controlled trial, we randomly assigned 142 patients with chronic moderate-to-severe plaque psoriasis ...
| Also Ranks for: Chronic Plaque Psoriasis | ixekizumab placebo | pasi score | monoclonal antibody | 12 weeks |
Treatment Patterns and Health Care Costs for Patients With Psoriatic Arthritis on Biologic Therapy: A Retrospective Cohort Study
[ PUBLICATION ]
BACKGROUND: Biologic therapies have been used in patients with psoriatic arthritis (PsA) who have been inadequately treated with conventional disease-modifying anti-rheumatic drugs (DMARDs).
OBJECTIVE: Examine treatment patterns and health care costs among patients with PsAs who initiated biologic therapy either as monotherapy or adjunctively with traditional DMARDs.
METHODS: The MarketScan(®) database was used to identify adults with PsA who initiated therapy with a biologic (with first ...
| Also Ranks for: Biologic Therapy | treatment patterns | psoriatic arthritis | retrospective cohort study | psa patients |
BACKGROUND: Previous studies have demonstrated that patients with psoriasis have higher rates of comorbidities compared to the general population. Despite the clinical and economic burden of psoriatic disease, there have been few large-scale observational studies focused on this condition.
OBJECTIVE: To assess rates of cardiovascular, autoimmune, infectious and other conditions in patients with psoriasis or psoriatic arthritis (PSA).
METHODS: The data for this retrospective study were ...
| Also Ranks for: Psoriatic Arthritis | patients psoriasis | incidence rates | cardiovascular diseases | retrospective studies |
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis
[ PUBLICATION ]
BACKGROUND: Itching is a profoundly distressing symptom for many patients with psoriasis, but it has not been rigorously studied using validated tools for this condition.
OBJECTIVES: This study investigated the psychometric properties of the Itch Numeric Rating Scale (Itch NRS), a single-item patient-reported outcome (PRO) measuring the worst itching severity due to psoriasis in the past 24 h.
METHODS: Using disease-specific clinician-rated and PRO data from one phase II and three phase ...
| Also Ranks for: Plaque Psoriasis | psychometric properties | itch nrs | baseline week | rating scale |
BACKGROUND: Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance.
OBJECTIVES: To investigate, in a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19-directed IL-23 antibody, vs. placebo in patients with moderate-to-severe plaque psoriasis.
METHODS: Adult patients were randomized 1 : 1 : 1 : 1 to receive placebo (n = 52), mirikizumab 30 mg (n = 51), ...
| Also Ranks for: Plaque Psoriasis | patients mirikizumab | efficacy safety | randomized phase | placebo pasi |
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
[ PUBLICATION ]
BACKGROUND: Itch is a prevalent symptom of psoriasis that impacts quality of life.
OBJECTIVE: We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3).
METHODS: The itch numeric rating scale evaluated psoriasis itch severity in all 3 trials. Skin pain was assessed by skin pain visual analog ...
| Also Ranks for: Skin Pain | psoriasis symptoms | ixekizumab patients | itch severity | baseline week |
BACKGROUND: The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown.
OBJECTIVE: We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis.
METHODS: We conducted a cross-sectional study of patients with plaque psoriasis (N=1153) and palmoplantar psoriasis (N=66) currently receiving systemic or light treatment for psoriasis.
RESULTS: Patients with ...
| Also Ranks for: Palmoplantar Psoriasis | severe plaque | life qol | healthrelated quality | clinical characteristics |
BACKGROUND: In patients with moderate-to-severe psoriasis, health-related quality of life (HRQOL) has been shown to improve in parallel with improvement in disease severity.
OBJECTIVES: To evaluate the role of pruritus (itch) in mediating the relationship between improvements in disease severity and HRQOL.
METHODS: Data from a phase 2 clinical trial, in which 142 patients with moderate-to-severe plaque psoriasis received ixekizumab or placebo, were used for this posthoc analysis. ...
| Also Ranks for: Life Hrqol | pruritus psoriasis | total score | quality dlqi | severity pasi |
BACKGROUND: Early identification of responsiveness to biologic treatments in psoriasis has significant clinical and economic implications.
OBJECTIVES: To evaluate whether early clinical improvements in Psoriasis Area and Severity Index (PASI) scores could predict subsequent clinical responses in patients treated with ixekizumab, an anti-interleukin-17 monoclonal antibody.
METHODS: This post hoc analysis was derived from a phase II study in patients with moderate-to-severe plaque ...
| Also Ranks for: Pasi Week | early clinical | plaque psoriasis | patients ixekizumab | subsequent response |
IntroductionPlaque psoriasis is a chronic skin disease where genital involvement is relatively common. Yet health care providers do not routinely evaluate psoriasis patients for genital involvement and patients do not readily initiate discussion of it.MethodsA qualitative study of 20 US patients with dermatologist-confirmed genital psoriasis (GenPs) and self-reported moderate-to-severe GenPs at screening was conducted to identify key GenPs symptoms and their impacts on health-related ...
| Also Ranks for: Genital Psoriasis | patients perspectives | sexual activity | genps symptoms | impact quality |
The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis
[ PUBLICATION ]
Plaque psoriasis (PP) and psoriatic arthritis (PsA) are autoinflammatory chronic conditions associated with skin involvement. Pruritus, or itching, is a prevalent and bothersome symptom in patients with PP and is associated with reduced health-related quality of life. The Worst Itch Numeric Rating Scale (WI-NRS) has been developed as a simple, single item with which to assess the patient-reported severity of this symptom at its most intense during the previous 24-hour period. Qualitative ...
| Also Ranks for: Psoriatic Arthritis | plaque psoriasis | patients psa | content validity | rating scale |
Emily Edson‐Heredia: Influence Statistics
| Concept | World rank |
|---|---|
| doses pasi | #1 |
| dlqi hrqol | #1 |
| pasi association pasi | #1 |
| week sobel tests | #1 |
| sobel tests | #1 |
| pso questionnaire | #1 |
| feelings domain | #1 |
| pasi pruritus improvement | #1 |
| mediator disease severity | #1 |
| pasi sobel tests | #1 |
| association pasi dlqi | #1 |
| nct02899988 | #1 |
| challenging body | #1 |
| pruritus mediator | #1 |
| improvements disease severity | #1 |
| association pasi improvement | #1 |
| psoriasis treatment responses | #1 |
| dlqi total score | #1 |
| improvement disease severity | #1 |
| severity ppasi | #1 |
| improvement dlqi | #1 |
| pasi improvement improvement | #1 |
| pruritus improvement improvements | #1 |
| challenging body areas | #2 |
| ppvs 89 | #2 |
| costs pediatric psoriasis | #2 |
| rates dlqi | #2 |
| hair loss symptoms | #2 |
| eyelash loss 82 | #2 |
| accompanying photoguides | #2 |
| treatment patterns healthcare | #2 |
| 126 37 years | #2 |
| costs psoriasis severity | #2 |
| pasi score improvements | #2 |
| worst itching severity | #2 |
| signs scores | #2 |
| aa signs symptoms | #2 |
| ppasi week | #2 |
| adults alopecia areata | #2 |
| ixekizumab maintenance treatment | #2 |
Key People For Alopecia Areata
Emily Edson‐Heredia:Expert Impact
Concepts for whichEmily Edson‐Herediahas direct influence:Alopecia areata, Work productivity, Touch avoidance, Psoriatic arthritis, Biologic therapy, Palmoplantar psoriasis, Content validity, Plaque psoriasis.
Emily Edson‐Heredia:KOL impact
Concepts related to the work of other authors for whichfor which Emily Edson‐Heredia has influence:Psoriatic arthritis, Th17 cells, Patients psoriasis, Monoclonal antibodies, Work productivity, Atopic dermatitis, Biologic agents.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |